RxDoctor Payments Data

Michael Notarianni, MD

Cardiovascular Disease · Arlington, VANPI 1487658357

Payments from drug & device makers

$1,560in general payments, 2019–2025

Across 68 payments — averaging $22.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$284
  • Amgen$243
  • Boston Scientific$184
  • Pfizer$161
  • E.r. Squibb & Sons, L.L.C.$123
  • Scpharmaceuticals Inc.$99
  • plus $466 from 15 others

What the payments were for

  • Food & beverage$1,52298%
  • Education$382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,560 in reported general payments places this provider in the 50th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$339,847
Medicare patients
1,400
Services billed
4,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban253$378,243
XareltoRivaroxaban58$77,088
EntrestoSacubitril/Valsartan34$51,649
MultaqDronedarone Hcl15$29,802
Repatha SureclickEvolocumab19$23,015
Praluent PenAlirocumab14$9,629
Metoprolol Succinate293$5,223
Atorvastatin Calcium268$3,574
Nebivolol Hcl48$3,572
Eplerenone14$2,031
Valsartan39$1,942
Rosuvastatin Calcium144$1,661
Losartan Potassium118$1,166
Lisinopril98$1,059
Amlodipine Besylate165$964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$161$378,243253 claims
Johnson & JohnsonXarelto$48$77,08858 claims
NovartisEntresto$284$51,64934 claims
Sanofi-aventis U.S. LLCMultaq$38$29,80215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →